2. Search Result
Search Result
Results for "

circadian rhythms

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

3

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148765
    CLK8

    		Cryptochrome Metabolic Disease Cancer
    CLK8 is a potent and specific CLOCK inhibitor that can disrupt the interaction between CLOCK and BMAL1 and interfere with nuclear translocation of CLOCK. CLK8 can be used for the research of disorders associated with dampened circadian rhythms .
    CLK8
  • HY-76632
    4-Hydroxyisophthalic acid

    		Cholinesterase (ChE) SOD Neurological Disease
    4-Hydroxyisophthalic acid activates antioxidant enzymes (such as catalase CAT and superoxide dismutase SOD), scavenges free radicals, and exhibits antioxidant property. 4-Hydroxyisophthalic acid activates AChE and BChE, enhances neuronal function and improves Tau-induced neurobehavioral defects. 4-Hydroxyisophthalic acid improves the cognitive defects, and ameliorates circadian rhythm disorders of fruit flies .
    4-Hydroxyisophthalic acid
  • HY-100813
    Saclofen
    3 Publications Verification

    		 GABA Receptor Neurological Disease Inflammation/Immunology
    Saclofen is an orally available competitive GABAB receptor antagonist with an IC50 of 7.8 μM, but it has a weaker antagonistic effect on GABAB1b and GABAB2 heterodimer recombinant receptors. Saclofen can inhibit the binding of baclofen (HY-B007) to rat cerebellar membranes and block the phase shifts in circadian rhythms caused by baclofen. Saclofen has also shown anti-inflammatory and analgesic effects in rats .
    Saclofen
  • HY-134194
    KL201
    1 Publications Verification

    		 Cryptochrome Metabolic Disease
    KL201 a circadian clock modulator, is a isoform-selective cryptochrome 1 (CRY1) stabilizer. KL201 has no stabilizing effect on CRY2. KL201 lengthens the period of circadian rhythms in cells and tissues .
    KL201
  • HY-108468
    KL001

    		Cryptochrome Metabolic Disease
    KL001 is a first-in-class cryptochrome (CRY, a flavoproteins that are sensitive to blue light, and is involved in the circadian rhythms of plants and animals) stabilizer which specifically interacts with CRY1 and CRY2. KL001 prevents ubiquitin-dependent degradation of CRY, resulting in lengthening of the circadian period. KL001 has the potential to control fasting hormone-induced gluconeogenesis .
    KL001
  • HY-148766
    VU661

    		Others Metabolic Disease
    VU661, a phenazine carboxamide, is a modulator of circadian rhythms to produce a period lengthening of the circadian rhythm. VU661 is a redox-active small molecule .
    VU661
  • HY-171300
    p38α inhibitor 8

    		p38 MAPK Casein Kinase Inflammation/Immunology
    p38α inhibitor 8 (Compound 1) exhibits inhibitory activity against p38α MAPK and CK1δ with IC50 of 0.21 µM and 0.202 µM [1]>.
    p38α inhibitor 8
  • HY-171301
    p38α MAPK/CK1δ inhibitor-1

    		p38 MAPK Casein Kinase Inflammation/Immunology
    p38α MAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38α MAPK and CK1δ with IC50 of 0.185 µM and 0.089 µM .
    p38α MAPK/CK1δ inhibitor-1
  • HY-116046
    GR 196429

    		Melatonin Receptor Others
    GR 196429 is a melatonin receptor agonist with some selectivity for the MT1 subtype. GR 196429 produces both sleep-promoting effects and alterations of circadian rhythm, as well as stimulating melatonin release in mice .
    GR 196429
  • HY-171292
    CK1δ-IN-9

    		Casein Kinase p38 MAPK Others
    CK1δ-IN-9 (Compound 8) is the inhibitor for casein kinase 1 that inhibits CK1δ with IC50 of 1.4 nM. CK1δ-IN-9 inhibits p38α and p38β with IC50 of 0.25 μM and 0.78 μM. CK1δ-IN-9 exhibits pharmacokinetic characteristics with a good oral bioavailability (70%) and a moderate clearance .
    CK1δ-IN-9
  • HY-145967
    FT709
    1 Publications Verification

    		 Deubiquitinase Cancer
    FT709 is a potent and selective USP9X inhibitor, an IC50 of 82 nM. USP9X has been linked with centrosome function, chromosome alignment during mitosis, EGF receptor degradation, chemo-sensitization, and circadian rhythms .
    FT709
  • HY-128677
    NCC007

    		Casein Kinase Neurological Disease
    NCC007 is a dual casein kinase Iα (CKIα) and δ (CKIδ) inhibitor with IC50s of 1.8 and 3.6 μM, respectively. NCC007 can be used in research of modulating mammalian circadian rhythms .
    NCC007
  • HY-131947
    DH97-7

    		Melatonin Receptor Neurological Disease
    DH97 is a potent melatonin receptor 2 (MT2) antagonist with Ki values of 252 nM and 1100 nM for MT2 and MT1, respectively .
    DH97-7
  • HY-171278
    Casein kinase 1δ-IN-28

    		Casein Kinase Metabolic Disease Cancer
    Casein kinase 1δ-IN-28 (Compound 4) is the inhibitor for CK1ε with an IC50 of 0.0146 μM. Casein kinase 1δ-IN-28 exhibits a metabolite rate in human liver microsomes of 52% .
    Casein kinase 1δ-IN-28
  • HY-170862
    E3 Ligase Ligand-linker Conjugate 163

    		E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 163 is the E3 ligase ligand (E3 ligase Ligand 58, HY-170861)-linker conjugate part of AH078 (HY-170859). AH078 is a PROTAC that targets the degradation of CK1δ and CK1ε, and can be used for research related to circadian rhythm disorders .
    E3 Ligase Ligand-linker Conjugate 163
  • HY-115519
    (E/Z)-GO289
    2 Publications Verification

    		 Casein Kinase Cancer
    (E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC50=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function .
    (E/Z)-GO289
  • HY-104064
    1A-116
    5 Publications Verification

    		 Ras Apoptosis Cancer
    1A-116, a potent Rac1 inhibitor, is specific for W56 residues, can prevent EGF-induced Rac1 activation and block Rac1-P-Rex1 interaction. 1A-116 can induce apoptosis and inhibit cell proliferation, migration and cycle progression in a concentration-dependent manner. 1A-116 also demonstrates a high antimetastatic activity in vivo .
    1A-116
  • HY-106136
    TIK-301

    PD-6735; LY-156735

    		 Melatonin Receptor 5-HT Receptor Neurological Disease
    TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT1 and MT2 receptors agonist with Kis of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT2B/5-HT2C receptors antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment .
    TIK-301
  • HY-157521
    AANAT-IN-1

    		Acyltransferase Endocrinology
    AANAT-IN-1 (compound 30) is a potent inhibitor (IC50: 10μM) of aralkylamine N-acetyltransferase (AANAT). AANAT is responsible for the synthesis of melatonin, which is involved in disorders such as seasonal affective disorder (SAD) in which melatonin levels are abnormally high .
    AANAT-IN-1
  • HY-162336
    Casein kinase 1δ-IN-15

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-15 is an inhibitor for casein kinase 1 (CK1δ), with an IC50 of 0.045 μM .
    Casein kinase 1δ-IN-15
  • HY-P10290
    Neuropeptide Y (human) free acid

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide Y (human) free acid is the deamidated form of Neuropeptide Y (human, rat, mouse) (HY-P0198). The amidation of Neuropeptide Y C-terminal tyrosine is critical for its function. Non-amidated Neuropeptide Y fails to elicit G protein signaling .
    Neuropeptide Y (human) free acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: